BioCentury | Jan 18, 2019
Product R&D

Modality moves at Vertex

In licensing a suite of newly discovered gene editing tools, Vertex Pharmaceuticals Inc. is broadening its options for solving problems that its core small molecule technology can’t address. On Jan. 3, Vertex announced a deal...
Items per page:
1 - 1 of 1